Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference
Applied Therapeutics (Nasdaq: APLT), a clinical-stage biopharmaceutical company, will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 10:00 a.m. ET. Investors can access the webcast on their website, with a replay available afterward.
The company is focused on developing drug candidates for high unmet medical needs, including AT-007 for Galactosemia and AT-001 for Diabetic Cardiomyopathy. Their clinical trials seek to address critical health issues in rare diseases.
- None.
- None.
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 at 10:00 a.m. ET.
Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. A pediatric Galactosemia study commenced in June 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.
Contacts
Investors:
Maghan Meyers or Brendan Burns
(212) 600-1902 or
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
FAQ
When will Applied Therapeutics present at the UBS Global Healthcare Conference?
Where can I find the webcast for Applied Therapeutics' conference presentation?
What is the focus of Applied Therapeutics' drug development?
What is the ticker symbol for Applied Therapeutics?
What are the lead drug candidates developed by Applied Therapeutics?
